Your session is about to expire
← Back to Search
Anti-metabolites
POLF regimen for Gastric Cancer
Phase 2
Waitlist Available
Led By Jie Liu, M.D.
Research Sponsored by Huashan Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
pathologically confirmed gastric cancer AJCC stage III or IV
measurable disease based on CT or endoscopy exam
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
Study Summary
phase II study of weekly metronomic chemotherapy using weekly Paclitaxel, Oxaliplatin, Leucovorin and 5-FU (POLF) in patients with advanced gastric cancer
Eligible Conditions
- Gastric Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
response rate
Secondary outcome measures
adverse events
overall survival
progression free survival
Trial Design
1Treatment groups
Experimental Treatment
Group I: POLF regimenExperimental Treatment1 Intervention
Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly
Find a Location
Who is running the clinical trial?
Huashan HospitalLead Sponsor
302 Previous Clinical Trials
14,685,337 Total Patients Enrolled
Seattle Integrative Cancer CenterUNKNOWN
Jie Liu, M.D.Principal InvestigatorHuashan Hospital
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger